Publications by authors named "B G Gustavsson"

Article Synopsis
  • 5-Fluorouracil (5-FU) is a primary treatment for colorectal cancer and is often combined with leucovorin (LV) to enhance its effectiveness by targeting thymidylate synthase (TS).
  • The study compared Arfolitixorin (Arfo), an active form of folate, to LV in combination with 5-FU in patients with colorectal cancer liver metastases to see which produces better TS inhibition and folate levels.
  • Results showed that Arfo led to significantly higher levels of folate (MeTHF) and increased TS inhibition compared to LV, indicating that Arfo may be a more effective option, though the difference in TS inhibition wasn't statistically significant.
View Article and Find Full Text PDF

: Interleukin-6 is dysregulated in multiple pathological conditions, e.g., cancer and inflammatory diseases.

View Article and Find Full Text PDF

The Swedish Childhood Tumor Biobank (BTB) is a nonprofit national infrastructure for collecting tissue samples and genomic data from pediatric patients diagnosed with central nervous system (CNS) and other solid tumors. The BTB is built on a multidisciplinary network established to provide the scientific community with standardized biospecimens and genomic data, thereby improving knowledge of the biology, treatment and outcome of childhood tumors. As of 2022, over 1100 fresh-frozen tumor samples are available for researchers.

View Article and Find Full Text PDF

The combination of 5-fluorouracil (5-FU) and leucovorin (LV) forms the chemotherapy backbone for patients with colorectal cancer. However, the LV administration is often standardized and not based on robust scientific data. To address these issues, a randomized pharmacokinetics study was performed in patients with colon cancer.

View Article and Find Full Text PDF

Background: Brain tumours are the most common solid tumours in childhood. Half of these tumours occur in the posterior fossa, where surgical removal is complicated by the risk of cerebellar mutism syndrome, of which postoperative speech impairment (POSI) is a cardinal symptom, in up to 25% of patients. The surgical approach to midline tumours, mostly undertaken by transvermian or telovelar routes, has been proposed to influence the risk of POSI.

View Article and Find Full Text PDF